ProNAi Therapeutics Obtains $59,500,000 Series D Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=211c8ccc-2d1d-4d89-a69e-eb6ecf6bf621
Date
4/22/2014
Company Name
ProNAi Therapeutics
Mailing Address
46701 Commerce Center Drive Plymouth, MI 48170 USA
Company Description
ProNAi Therapeutics, Inc. is an emerging biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.
Website
http://www.pronai.com
Transaction Type
Venture Equity
Transaction Amount
$59,500,000
Transaction Round
Series D
Proceeds Purposes
The Series D funding will be used to advance PNT2258 in several Phase II clinical studies in patients with relapsed or treatment refractory non-Hodgkin’s lymphoma including those with diffuse large B-cell lymphoma (DLBCL),Richter’s transformation, and follicular lymphoma (FL). Proceeds will also be used to support drug manufacturing, advance development of preclinical drug candidates, and build ProNAi’s organization in Michigan.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor